Difference between revisions of "Template:Adrenergic receptor modulators"
Jump to navigation
Jump to search
blackwiki>Medgirl131 |
m (274 revisions imported) |
||
| (10 intermediate revisions by 6 users not shown) | |||
| Line 37: | Line 37: | ||
* [[Naphazoline]] | * [[Naphazoline]] | ||
* [[Norepinephrine]] | * [[Norepinephrine]] | ||
| − | * [[Octopamine | + | * [[Octopamine]] |
* [[Oxymetazoline]] | * [[Oxymetazoline]] | ||
* [[Phenylephrine]] | * [[Phenylephrine]] | ||
| Line 56: | Line 56: | ||
* [[Arotinolol]] | * [[Arotinolol]] | ||
* [[Atiprosin]] | * [[Atiprosin]] | ||
| − | * [[Atypical antipsychotic]]s (e.g., [[clozapine]], [[olanzapine]], [[quetiapine]], [[risperidone]]) | + | * [[Atypical antipsychotic]]s (e.g., [[brexpiprazole]], [[clozapine]], [[olanzapine]], [[quetiapine]], [[risperidone]]) |
* [[Benoxathian]] | * [[Benoxathian]] | ||
* [[Buflomedil]] | * [[Buflomedil]] | ||
| Line 81: | Line 81: | ||
* [[Naftopidil]] | * [[Naftopidil]] | ||
* [[Nantenine]] | * [[Nantenine]] | ||
| − | |||
* [[Neldazosin]] | * [[Neldazosin]] | ||
* [[Niaprazine]] | * [[Niaprazine]] | ||
| Line 88: | Line 87: | ||
* [[Pardoprunox]] | * [[Pardoprunox]] | ||
* [[Pelanserin]] | * [[Pelanserin]] | ||
| + | * [[Perlapine]] | ||
* [[Phendioxan]] | * [[Phendioxan]] | ||
* [[Phenoxybenzamine]] | * [[Phenoxybenzamine]] | ||
* [[Phentolamine]] | * [[Phentolamine]] | ||
| + | * [[Phenylpiperazine]] [[antidepressant]]s (e.g., [[hydroxynefazodone]], [[nefazodone]], [[trazodone]], [[triazoledione]]) | ||
* [[Piperoxan]] | * [[Piperoxan]] | ||
* [[Prazosin]] | * [[Prazosin]] | ||
* [[Quinazosin]] | * [[Quinazosin]] | ||
| + | * [[Quinidine]] | ||
* [[Ritanserin]] | * [[Ritanserin]] | ||
* [[Silodosin]] | * [[Silodosin]] | ||
| Line 102: | Line 104: | ||
* [[Tiodazosin]] | * [[Tiodazosin]] | ||
* [[Tolazoline]] | * [[Tolazoline]] | ||
| − | |||
* [[Tetracyclic antidepressant]]s (e.g., [[amoxapine]], [[maprotiline]], [[mianserin]]) | * [[Tetracyclic antidepressant]]s (e.g., [[amoxapine]], [[maprotiline]], [[mianserin]]) | ||
* [[Tricyclic antidepressant]]s (e.g., [[amitriptyline]], [[clomipramine]], [[doxepin]], [[imipramine]], [[trimipramine]]) | * [[Tricyclic antidepressant]]s (e.g., [[amitriptyline]], [[clomipramine]], [[doxepin]], [[imipramine]], [[trimipramine]]) | ||
| Line 168: | Line 169: | ||
* ''Antagonists:'' [[Pyrimidinylpiperazine|1-PP]] | * ''Antagonists:'' [[Pyrimidinylpiperazine|1-PP]] | ||
* [[Adimolol]] | * [[Adimolol]] | ||
| + | * [[Amesergide]] | ||
* [[Aptazapine]] | * [[Aptazapine]] | ||
* [[Atipamezole]] | * [[Atipamezole]] | ||
| − | * [[Atypical antipsychotic]]s (e.g., [[asenapine]], [[clozapine]], [[lurasidone]], [[paliperidone]], [[quetiapine]], [[risperidone]], [[zotepine]]) | + | * [[Atypical antipsychotic]]s (e.g., [[asenapine]], [[brexpiprazole]], [[clozapine]], [[lurasidone]], [[olanzapine]], [[paliperidone]], [[quetiapine]], [[risperidone]], [[zotepine]]) |
| − | * [[Azapirone]]s (e.g., [[buspirone]], [[tandospirone]]) | + | * [[Azapirone]]s (e.g., [[buspirone]], [[gepirone]], [[ipsapirone]], [[tandospirone]]) |
* [[BRL-44408]] | * [[BRL-44408]] | ||
* [[Buflomedil]] | * [[Buflomedil]] | ||
| Line 184: | Line 186: | ||
* [[Mirtazapine]] | * [[Mirtazapine]] | ||
* [[NAN-190]] | * [[NAN-190]] | ||
| − | |||
* [[Pardoprunox]] | * [[Pardoprunox]] | ||
* [[Phentolamine]] | * [[Phentolamine]] | ||
| Line 389: | Line 390: | ||
* [[Xipranolol]] | * [[Xipranolol]] | ||
| − | + | |group4 = See<br/>also | |
| − | + | |list4 = *[[List of adrenergic drugs]] | |
| − | |||
| − | |||
| − | * | ||
| − | |||
| − | |||
| − | |||
| − | }} | + | |
| − | <noinclude> | + | }}<noinclude> |
{{documentation | content = | {{documentation | content = | ||
{{collapsible option}} | {{collapsible option}} | ||
| − | |||
[[Category:Drug templates by receptor, channel, or pump]] | [[Category:Drug templates by receptor, channel, or pump]] | ||
}}</noinclude> | }}</noinclude> | ||
Latest revision as of 10:17, 18 October 2020
50px Template documentation
Initial visibility: currently defaults to autocollapse
To set this template's initial visibility, the |state= parameter may be used:
|state=collapsed:{{Adrenergic receptor modulators|state=collapsed}}to show the template collapsed, i.e., hidden apart from its title bar|state=expanded:{{Adrenergic receptor modulators|state=expanded}}to show the template expanded, i.e., fully visible|state=autocollapse:{{Adrenergic receptor modulators|state=autocollapse}}
If the |state= parameter in the template on this page is not set, the template's initial visibility is taken from the |default= parameter in the Collapsible option template. For the template on this page, that currently evaluates to autocollapse.
| Editors can experiment in this template's sandbox (edit | diff) and testcases (create) pages. Subpages of this template. |